Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andrew Burrows
Nanobionic enhancement of plant growth via copper nanoclusters in Raphanus sativus
Abstract Copper-based nanobionics offer a promising route to enhance photosynthetic efficiency and crop productivity. In this study the application of two photoluminescent copper nanomaterials, cysteine-stabilized copper nanoclusters (Cu-Cys) and copper-doped carbon nanoassemblies (Cu-CNAs) were used in studies of Raphanus sativus (radish), evaluating their uptake, physiological impact, and metabolomic response.
Wanarra: a vast landscape set to be protected
The period of destocking means it is a landscape already on a path of recovery. “That decade of care is a gift of time,” Fiamma says. “It would allow us to focus on managing other threats like introduced species, fire and climate – rather than just trying to repair damage.” A place of cultural significance for Traditional Custodians Wanarra is a living cultural landscape for the Badimia People and the Widi Mob of the Yamatji Nation.
A Restatement of the English Law of Contract
Following the success of the first edition, this is the fully updated second edition of A Restatement of the English Law of Contract. Designed to enhance the accessibility of the common law the Restatement comprises a number of clear and succinct rules, fully explained by a supporting commentary, which set out the general law of contract in England and Wales.
Regulatory reporting controls as a strategic advantage
There is continuing focus and heightened expectations around governance, processes and controls in relation to Financial & Regulatory Reporting. Over the last few years firms have invested to uplift controls environments around regulatory reporting in response to the Prudential Regulation Authority (“PRA”) Dear CEO letter of 2021 setting out the Regulator’s thematic findings on reliability of Regulatory Reporting.
PRA Basel 3.1 Policy Statement - PS 17/23
December 2023 As announced in September 2023, the PRA has published the first package of near-final rules for the UK implementation of Basel 3.1. The first policy statement (PS17/23) covers market risk, credit valuation adjustment risk, counterparty credit risk and operational risk. A second policy statement, on credit risk, the output floor and disclosure requirements, is expected in Q2 2024.
Basel 3.1
Basel 3.1 Basel 3.1 Basel 3.1 1000 The implementation of Basel 3.1 is one of the biggest priorities for banks operating in the UK as they move into 2024. For many, the PRA’s recent announcement pushing the go-live date back to 1 July 2025 may have prompted a positive response that there is now a further six months to prepare.
Tailoring 3D Printed Micro‐Structured Carbons for Adsorption
Abstract The manufacture of tailored carbon-based adsorbent structures with exceptionally low-pressure drops and improved kinetics using stereolithographic 3D printing is presented. Adsorbent structures are printed from commercial resins with square, circular, and hexagonal cross-sectional microchannels. These structures can reduce energy use by 50–95% compared to conventional carbon-packed beds.
Commercialisation and applications: general discussion
Commercialisation and applications: general discussion You have access to this article Please wait while we load your content... Something went wrong. Try again?
Fundamental studies and design of MOFs: general discussion
Fundamental studies and design of MOFs: general discussion M. Attfield, V. K. Au, L. Brammer, A. Burrows, V. Butova, J. Casaban, G. Chanteux, I. Cooley, H. Doan, D. Fairen-Jimenez, R. Fucci, P. Horcajada, Z. Huang, S. James, C. Lavenn, A. Laybourn, J. Li, Y. Li, N. Ma, S. D. Pike, D. N. Rainer, G. Sánchez, M. Schroder, C. Serre, M. Shivanna, M. Shozi, O. Thomas, G. Toft, O. Yaghi, S. Yang, M. Zaworotko and G.
RSC Prize and Award talk: 2020 Sustainable Water Award: general discussion
RSC Prize and Award talk: 2020 Sustainable Water Award: general discussion You have access to this article Please wait while we load your content... Something went wrong. Try again?
Help us shape the future of Agile marketing
As a marketer, do you ever feel like you’re being asked to play a game in which the rules are still being written and on a field that is constantly changing? Oh, and you’re also blind-folded? Yesterday’s customers are today’s competitors. Today’s pipe dreams are tomorrow’s products. The rate of change has never been so fast. And thus the need for Agile marketers has never been so great. But what is an Agile marketer?
Advanced characterisation techniques: multi-scale, in situ, and time-resolved: general discussion
Advanced characterisation techniques: multi-scale, in situ, and time-resolved: general discussion Lee Brammer, Andrew D. Burrows, Samantha Yu-ling Chong, Gavin Craig, Jack Evans, Omar Farha, David Farrusseng, Michael Fischer, Andrew Goodwin, Zhehao Huang, Ben Johnson, Stefan Kaskel, Susumu Kitagawa, Christophe Lavenn, Alfred Y. Lee, Jet-Sing M. Lee, Ryotaro Matsuda, Anthony E. Phillips, Daniel N. Rainer, Matthew R.
Towards complex systems and devices: general discussion
Towards complex systems and devices: general discussion You have access to this article Please wait while we load your content... Something went wrong. Try again?
Military Veterans in Agriculture - New Ag International eBook Series
The agri community is increasingly seeking out untapped resources when it comes to people and talent - from attracting more women into the space, helping recruit a younger generation and shining the spotlight on diversity and inclusion. In this new eBook series, New Ag International is taking a closer look at some of these areas, starting with the veteran and military-affiliated community.
REPORT: The Agriculture Community 2020: The People Behind the Product
Explore or download the full interactive report by clicking on the image above (or here). The agriculture industry, like most others at the moment, is assessing where there are untapped skills from currently under represented groups of people. Organizations are increasingly looking at diversity and inclusion in the workforce, as well as outreach schemes for attracting more women and a younger generation to the industry.
Inclusion of viologen cations leads to switchable metal-organic frameworks
This article is Open Access Please wait while we load your content... Something went wrong. Try again?
Cooperative phenomena in framework materials Home
About this collection We are delighted to share with you a selection of the papers associated with a Faraday Discussion on Cooperative phenomena. More information about the event may be found here: http://rsc.li/framework-fd2020. Additional articles will be added to the collection as they are published. The final versions of all the articles presented and a record of the live discussions will be published after the event.
Women in Pharma: 44% of pharma professionals think that women are under represented in their organization
44% of pharma professionals think that women are under represented in their organization according to new data from an Informa Connect Life Sciences study. The April 2020 study was conducted on 432 life sciences professionals from the pharma, biotech, medical device and regulatory industries around the world, with the responses presented in the Diversity, Inclusion and Sustainability in the Global Life Sciences Industry 2020 report. Explore or download the full study report here.
Looking to 2030 Report: The Future of the Global Life Sciences and Pharma Industry
With the spread of COVID-19, the future is probably more uncertain now than at any point in recent memory. However, as we enter a new decade, as well as uncertainty, the next ten years present huge opportunities for the pharma, biotech, medical device and regulatory industries. What changes will we see in emerging therapies and technologies and who will be driving that change?
Regulatory challenges for Software as Medical Device (SaMD) and AI
Software as Medical Device (SaMD) and Artificial Intelligence are the future of MedTech, yet they both bring their own set of regulatory challenges. We asked six industry experts for their views on the regultory challenges and impact SaMD and AI will have on the medical device landscape - read their full responses in the interactive eBook below (or click here): The questions we asked included:. What are the biggest regulatory challenges for SaMD at the moment?
Measure Twice, Treat Once: Navigating the regulatory landscape of assay development to ensure high-quality CGT products
Research and development of new cellular and gene therapy (CGT) products to treat different therapeutic indications is growing rapidly, and many candidates are progressing in clinical development. CGTs must be manufactured using processes that ensure a predefined quality of products. Careful monitoring of critical quality attributes and other product characteristics is needed in process development and in manufacturing to ensure product safety and efficacy.
Life Sciences in 2020: Predictions from industry insiders
With new technologies, emerging therapeutics, regulatory changes and an increasingly volatile political landscape in much of the world, the life sciences industries face an important year ahead. Marking the start of a new decade, 2020 could see big developments in industries that traditionally move slowly. To read our interactive report on 2020 predictions click here or on the image below.
The state of manufacturing and commercialization of microbiome therapeutics - Data report analysis
Informa Connect Life Sciences recently (June 2019) conducted a survey of microbiome therapeutics professionals from around the world on how they saw the future landscape of the emerging field. The 89 respondents, representing pharma and biotech (38%), academia (20%), service and technology providers (18%) and CROs/CDMOs (9%), offered a number of insights on manufacturing and commercialization within the industry and here we take a deep dive into that data.
Biotech Week Boston 2019 Unwrapped
In September Biotech Week Boston welcomed over 5000 life sciences professionals for an incredible week across 12 co-located events. Delegates from more than 30 countries filled a bustling exhibit hall and overflowing rooms to discuss the latest research in bioprocessing, cell and gene therapies and microbiome therapeutics. Alongside Leaders In, here we highlight some of the key speakers, sessions, events and interviews that went on over the week in an interactive flip book.
Can the gut microbiome be used to treat autism and Parkinson's?
Andrew Burrows 26 Feb 2018 "The gut microbiome, we feel from the data that we have today, contributes or causes a lot of the diseases associated with central nervous system disorders." At EBDâs BIO-Europe conference (November 2017) in Berlin, David Donabedian, CEO of Axial Biotherapeutics, spoke to Mike Ward, head of content for Informa Pharma Insights, about the company's research into how the gut microbiome could be connected to both autism and Parkinsonâs, and how they are moving...
7 predictions for how clinical trials will look in 10 years
The way clinical trials are being run is gradually changing with the implementation of new technologies. AI, wearables, virtual and in silico trials, digital biomarkers and personalized medicine are all likely to play a major role in the future of clinical trials. Here seven clinical experts representing pharma, CROs, patient groups, academia and health futurism make their predictions for how clinical trials will look in 10 years time.
Thinking about statutes interpretation interaction improvement | English legal system
*This title has one or more locked files and access is given only to instructors adopting the textbook for their class. We need to enforce this strictly so that solutions are not made available to students. To gain access to locked resources you either need first to sign in or register for an account. These resources are provided free of charge by Cambridge University Press with permission of the author of the corresponding work, but are subject to copyright.
Thinking about statutes interpretation interaction improvement | English legal system
*This title has one or more locked files and access is given only to lecturers adopting the textbook for their class. We need to enforce this strictly so that solutions are not made available to students. To gain access to locked resources you either need first to sign in or register for an account. These resources are provided free of charge by Cambridge University Press with permission of the author of the corresponding work, but are subject to copyright.
9 questions that still need to be answered about technology in clinical trials
Over the last six months we have spoken to dozens of industry experts about every aspect of technology in clinical trials. One thing that has stood out is that there are more questions than answers around the tech revolution at the moment. Here we have gathered some of the biggest questions and how industry leaders are attempting to answer them. 1) Which technology platforms are most shaping the way trials are run?
Quiz - How much do you know about the cell & gene therapy industry in 2018?
2018 jump started with large gains for advanced therapies and headline-making IPOs, finance rounds, and partnership agreements. Investors signaled their willingness to invest early, with several companies raising funds in Series A. With over 950 clinical trials underway in the space and over $3.8billion in IPO financings in Q1, there is no surprise that many see the sector as one to watch. The real question is, how much do you know about the industry you work in?
MHealth in clinical trials: 79% of companies increasing usage - data report analysis
KNect365 recently conducted one of the biggest surveys of its kind of clinical trial professionals asking about the most hyped areas of clinical trials today and whether they are actually impacting the way studies are run. 199 clinical trial professionals from pharma and biotechs (24%), CROs (23%), service providers (21%), consultancies (11%), sites (6%), academia (5%) and patient groups (2%) completed the survey, largely split between North America (55%) and Europe (33%).
The patient-centricity gap in clinical trials - data report analysis
KNect365 recently conducted one of the biggest surveys of its kind of clinical trial professionals asking about the most hyped areas of clinical trials today and whether they are actually impacting the way studies are run. 199 clinical trial professionals from pharma and biotechs (24%), CROs (23%), service providers (21%), consultancies (11%), sites (6%), academia (5%) and patient groups (2%) completed the survey, largely split between North America (55%) and Europe (33%).
6 ways clinical trials are changing
In this interview for PCT TV we asked Anna Matranga, Strategic Sourcing R&D at AMC Alliances & Consulting, to predict how clinical trials will change in the next five to ten years. She picked out six areas she thinks will see the biggest change.
'The microbiome is the next paradigm shift in science' - Second Genome CEO
'The next paradigm shift is going to be the microbiome. Microbes live in us, on us and around us; we can't avoid them and if you tried to sterilize your body you would die.
Managing clinical data between different sources and stakeholders
Which technologies do you think will have the biggest impact on clinical trials? RS: The big challenge at the moment is to manage all the analytical and Artificial Intelligence. We need technologies to support this, to manage all the big data that is coming out of clinical trials. What is really needed in clinical trials? We know that the process is long and complex... We need a technology that can combine and be one source.
Clinicians 'need to stop thinking in traditional terms and acting with yesterday’s logic' - Nick van Terheyden, MD, Incremental Healthcare
In this hard-hitting interview, Nick van Terheyden, MD (aka Dr Nick), Founder & CEO Incremental Healthcare, discusses the latest innovations in clinical data collection and handling and what is holding them back. It is part of our series on clinical data collection and management. With new technologies constantly appearing, there are numerous innovative ways to collect clinical data, which do you think currently are and will be the most effective?
Facing the challenges of finding investigative sites for clinical trials
We spoke to Dr. Diana Sims-Silbermann, Senior Trial Manager of Early Development and Clinical Pharmacology at Janssen, as part of PCT TV at Partnerships in Clinical Trials Europe (Nov 2017) about the difficulties in finding suitable investigative sites for clinical trials and the added complications of regulatory requirements. Here we pick out the key highlights, or you can watch the full interview below. What challenges are there in finding suitable investigative sites?
Clinical data: 9 experts reveal the biggest challenges
As part of our series on clinical data collection and management, we asked a range of clinical professionals from pharma, CROs, technology providers and associations about the biggest challenges around clinical data they face. We gathered answers from nine of them here. Explore other posts from the clinical data series here. 'With wearables the volume of data collected could be enormous. How much will it cost to collect and manage this data? Do we have the ability to do this cost effectively yet?
The most effective clinical trial data collection technologies - INDUSTRY VOICES
Data. Data. Data. Pharma and CROs have more clinical study data at their fingertips than ever before, but many feel they are not yet using it in the best way. Which technologies and strategies are most effective for generating reliable data? What benefits is this actually driving? What challenges still need to be overcome? In a new series, we explore these questions with some of the experts working to answer them every day.
The most effective clinical trial data collection technologies - INDUSTRY VOICES
Data. Data. Data. Pharma and CROs have more clinical study data at their fingertips than ever before, but many feel they are not yet using it in the best way. Which technologies and strategies are most effective for generating reliable data? What benefits is this actually driving? What challenges still need to be overcome? In a new series, we explore these questions with some of the experts working to answer them every day.
Bringing a cell therapy for Parkinson's disease into the clinic - Stefan Irion, Memorial Sloan Kettering
As Program Manager at Memorial Sloan Kettering, Stefan Irion is working under the leadership of Lorenz Studer and Viviane Tabar on bringing a new cell therapy for Parkinson's disease into the clinic. We caught up with him at Biotech Week Boston in September 2017 - watch the interview or read everything Irion said below. ‘We hope to be in the clinic in the second quarter of 2018. We've licensed the technology to a company that will support the trial of the raw therapeutics.
The effect of metal distribution on the luminescence properties of mixed-lanthanide metal-organic frameworks
A series of lanthanide metal–organic frameworks (MOFs) of the general formula [Ln(Hodip)(H O)]·nH O (Sm, 1; Eu, 2; Gd, 3; Tb, 4; Dy, 5; Er, 6; H odip = 5,5?-oxydiisophthalic acid) have been prepared and shown crystallographically to have isostructural three-dimensional frameworks.
Clinical data from wearables: Quality, regulatory and privacy concerns
There's little doubt that wearables and smartphones have had a huge impact on clinical trials and will only continue to do so in the future. However, there are still major concerns around the quality, regulatory and privacy implications of acquiring data from these new technologies. We asked five experts working in clintech what they see as the biggest challenges with mHealth and how they can be overcome.
The future of clinical trials - INDUSTRY VOICES
Artificial Intelligence, mHealth, Internet of Things (IoMT), big data, social media; there's no doubt that technology is changing clinical trials. However, everyone has different ideas about how best to use these technologies and where they are taking the trials of the future. Additionally, with innovative trial designs, increasingly patient-centric approaches, biomarkers and personalised medicine, clinical trials could look very different in 5, 10 or 20 years.
Patient benefits of mobile technologies in clinical trials
This is an extract from an exclusive free whitepaper that explores whether clinical trials are truly patient-centric yet. Download the full report here. The smartphone and tablet have revolutionized the way that we communicate, play, socialize, exercise, and amuse ourselves. They also dramatically increase our access to information. There are apps that measure anything and everything. Most of us cannot imagine our lives without them.
MHealth in Clinical Trials Report: Just 37% of companies utilize technologies
Based on 261 responses representing pharma, CROs and service providers split across North America, Europe and Asia, the survey results offer an insight into perceptions and implementation of technological innovations in clinical trials today. The results reveal mHealth to be one of the brightest hopes within clinical trials, but also that a number of challenges first need to be overcome before full implementation. Of those surveyed, four separate technologies are predominantly used.
‘Too much weight placed on FDA approval of wearables,’ says UK health research expert
In a rapidly evolving digital landscape, the disruptive innovation of mobile technology, applications and so-called ‘wearable’ technology could be a complete game-changer for the healthcare sector. However, the potential for wearables and mobile apps to be used in clinical trials is raising all kinds of questions about legality, privacy and accuracy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andrew
Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack